To assess the efficacy and safety of olaparib maintenance monotherapy in the treatment of ovarian cancer

Trial Identifier: D0816C00012
Sponsor: AstraZeneca
NCTID:: NCT02476968
Start Date: September 2015
Primary Completion Date: April 2020
Study Completion Date: December 2021
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BG Plovdiv, BG, 4004
BG Plovdiv, BG, 4000
BG Sofia, BG, 1756
BG Sofia, BG, 1330
BG Sofia, BG, 1303
BG Sofia, BG, 1407
BG Varna, BG, 9010
CA, AB Calgary, AB, CA, T2N 4N2
CA, NS Halifax, NS, CA, B3H 2E2
CA, ON London, ON, CA, N6A 4L6
CA, Ontario Toronto, Ontario, CA, M5G 1X6
CA, QC Montreal, QC, CA, H3T 1E2
CA, QC Montreal, QC, CA, H2X 0A9
CZ Brno, CZ, 625 00
CZ Brno, CZ, 656 53
CZ Novy Jicin, CZ, 741 01
CZ Olomouc, CZ, 775 20
CZ Ostrava, CZ, 708 52
CZ Praha 2, CZ, 128 08
CZ Praha 5, CZ, 15000
ES Badalona, ES, 08916
ES Barcelona, ES, 08025
ES Burgos, ES, 09006
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28041
ES Madrid, ES, 28040
ES San Cristobal de La Laguna, ES, 38320
ES Sevilla, ES, 41009
ES Valencia, ES, 46010
ES Valencia, ES, 46026
ES Zaragoza, ES, 50009
GB Belfast, GB, BT9 7AB
GB Birmingham, GB, B18 7QH
GB Cardiff, GB, CF14 2TL
GB Glasgow, GB, G12 OYN
GB Leeds, GB, LS9 7TF
GB London, GB, SE1 9RT
GB Manchester, GB, M20 4BX
GB Newcastle upon Tyne, GB, NE7 7DN
GB Oxford, GB, OX3 7LJ
GB Swansea, GB, SA2 8QA
GB Taunton, GB, TA1 5DA
GB Wirral, GB, CH63 4JY
HU Budapest, HU, 1062
HU Budapest, HU, 1122
HU Budapest, HU, 1032
HU Debrecen, HU, 4032
HU Kecskemét, HU, 6000
HU Nyíregyháza, HU, 4400
IT BARI, IT, 70124
IT MILANO, IT, 20141
IT Napoli, IT, 80131
IT PERUGIA, IT, 06132
PL Bialystok, PL, 15-027
PL Gdansk, PL, 80-402
PL Kielce, PL, 25-734
PL Poznan, PL, 60-569
PL Poznań, PL